Inhibrx Biosciences Inc. (INBX) vs Taysha Gene Therapies, Inc. (TSHA)
A side-by-side comparison of Inhibrx Biosciences Inc. and Taysha Gene Therapies, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
INBX
Inhibrx Biosciences Inc.
$93.41HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TSHA
Taysha Gene Therapies, Inc.
$4.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — INBX vs TSHA
growth of $100 · dividends reinvested · last 6yINBX +457.8% (+33.2%/yr)TSHA -81.3% (-24.4%/yr)INBX compounded faster over this window
Log scale — wide-divergence pair
INBX TSHA
INBX vs TSHA: by the numbers
- •TSHA is the larger company ($1.40B vs $1.37B market cap).
- •Both run net losses; TSHA's is the smaller (-2728.04% vs -10773.46% net margin).
Metrics side by side
Valuation
| Metric | INBX | TSHA |
|---|---|---|
| P/S ratio | N/A | 256.01 |
| P/B ratio | N/A | 3.63 |
Profitability
| Metric | INBX | TSHA |
|---|---|---|
| Gross margin | -91.00% | 100.00% |
| Operating margin | -10386.54% | -1130.65% |
| Net margin | -10773.46% | -2728.04% |
| ROE | N/A | -38.64% |
| ROIC | -99.35% | -34.46% |
Growth (annualized)
| Metric | INBX | TSHA |
|---|---|---|
| Total return CAGR (5Y) | 27.64% | -25.17% |
Frequently asked
- How have INBX and TSHA total returns compared?
- Over the past 5 years, INBX delivered 27.64% and TSHA delivered -25.17% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.